The Integrin α4β1 (VLA‐4) as a therapeutic Target

MJ Elices - Ciba Foundation Symposium 189‐Cell Adhesion …, 2007 - Wiley Online Library
MJ Elices
Ciba Foundation Symposium 189‐Cell Adhesion and Human Disease …, 2007Wiley Online Library
Disease models in animals demonstrate that the leukocyte integrin α4β1 (VLA‐4) is a
suitable target for therapy in a number of chronic inflammatory disorders. While in vivo
studies have concentrated on the use of anti‐α4, antibodies as proof of concept tools,
repeated administration to combat human chronic inflammatory conditions is likely to require
small antagonists of α4β1. We have developed low molecular weight α4β1 inhibitors which
have shown therapeutic promise in animal models of chronic inflammation.
Summary
Disease models in animals demonstrate that the leukocyte integrin α4β1 (VLA‐4) is a suitable target for therapy in a number of chronic inflammatory disorders. While in vivo studies have concentrated on the use of anti‐α4, antibodies as proof of concept tools, repeated administration to combat human chronic inflammatory conditions is likely to require small antagonists of α4β1. We have developed low molecular weight α4β1 inhibitors which have shown therapeutic promise in animal models of chronic inflammation.
Wiley Online Library